Ramucirumab

雷莫西尤单抗

Report date: 2026/05/09 20:00:18

Base Information

Drug NameRamucirumab
Drug Alias NameAnti-flk-1 monoclonal antibody雷莫卢单抗雷姆赛卢单抗Anti-VEGFR 2 monoclonal antibodyRamucirumabum +[14] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[27] 
Global Approved IndicationsStomach NeoplasmsCarcinoma, HepatocellularGastrointestinal Stromal Tumors
Approved Indications in ChinaStomach Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2014/04/21
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[59] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDyax Pharma
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteInnovent Biologics IncEli Lilly And Company +[6] 
Inactive CompaniesImclone Systems CorporationNational Cancer InstituteImclone Llc +[4] 
Active IndicationsGastroesophageal Junction NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[9] 
Inactive IndicationsMetastatic breast cancerSolid tumoursUrethral Neoplasms +[18] 

Other Information

ATC CodeL01XC21
Related LinksWikipediaDrugBankKEGG